Publications by authors named "S Mavridou"

Mutations in genes encoding for proteins along the RAS-RAF-MEK-ERK pathway have been detected in a variety of tumor entities, including malignant melanoma, thyroid, colonic and ovarian carcinomas, and some sarcomas. Thus, a number of inhibitors of this pathway have been developed, whose antitumor potential is currently being assessed in different clinical trials. Up to now one drug of this category (vemurafenib) has been approved by the FDA and the European Commission for late-stage melanoma.

View Article and Find Full Text PDF

Scavenger receptor class B type I (SR-BI) facilitates the reverse transport of excess cholesterol from peripheral tissues to the liver via high-density lipoproteins. In steroidogenic tissues, SR-BI supplies cholesterol for steroid hormone production. We show here that the transcription of the human SR-BI gene is subject to feedback inhibition by glucocorticoid in adrenal and ovarian cells.

View Article and Find Full Text PDF
Article Synopsis
  • Smad proteins, critical for TGFbeta signaling in mammalian cells, consist of two main structured domains (MH1 and MH2) connected by a linker region that may influence their function in cross-signaling with other pathways.
  • The study involved creating Smad3 mutants with specific amino acid changes in the linker region, revealing that certain residues (like glutamine 222 and proline 229) are vital for Smad3's ability to oligomerize, accumulate in the nucleus, and bind to DNA after TGFbeta stimulation.
  • Interestingly, one mutant (asparagine 218 to alanine) showed increased activity, while another (P229A) reduced TGFbeta signaling when overexpressed, unders
View Article and Find Full Text PDF

Smad proteins are the key effectors of the transforming growth factor beta (TGFbeta) signaling pathway in mammalian cells. The importance of Smads for human physiology is documented by the identification and characterization of mutations that are frequently found in cancer patients. In the present study we have functionally characterized such a tumorigenic mutation in Smad4 (E330A) and shown that this mutant as well as a Smad3 mutant bearing the corresponding mutation (Smad3 E239A) failed to activate transcription in response to TGFbeta stimulation because of defects in homo-and hetero-oligomerization.

View Article and Find Full Text PDF

Transforming growth factor beta (TGFbeta) regulates transcriptional responses via activation of cytoplasmic effector proteins termed Smads. Following their phosphorylation by the type I TGFbeta receptor, Smads form oligomers and translocate to the nucleus where they activate the transcription of TGFbeta target genes in cooperation with nuclear cofactors and coactivators. In the present study, we have undertaken a deletion analysis of human Smad3 protein in order to characterize domains that are essential for transcriptional activation in mammalian cells.

View Article and Find Full Text PDF